{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:46:42Z","timestamp":1792392402483,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.pcad.2015.08.009","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T02:00:46Z","timestamp":1439431246000},"page":"267-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike"],"prefix":"10.1016","volume":"58","author":[{"given":"Francesco","family":"Franchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwhi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2015.08.009_bb0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","article-title":"Update on acute coronary syndromes: the pathologists' view","volume":"34","author":"Falk","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0020","first-page":"e344-246","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.08.009_bb0025","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0030","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(15)60243-4","article-title":"Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments","volume":"386","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.009_bb0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pcad.2015.08.009_bb0045","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0050","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2165\/11640880-000000000-00000","article-title":"The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day","volume":"72","author":"Angiolillo","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.pcad.2015.08.009_bb0055","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0060","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0065","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40256-013-0022-7","article-title":"Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents","volume":"13","author":"Angiolillo","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pcad.2015.08.009_bb0080","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0085","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0090","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.08.009_bb0095","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","article-title":"Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial","volume":"382","author":"Wiviott","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.009_bb0100","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0105","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0110","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0115","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0120","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","article-title":"Platelet thrombin receptor antagonism and atherothrombosis","volume":"31","author":"Angiolillo","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0130","doi-asserted-by":"crossref","DOI":"10.2217\/fca.15.50","article-title":"Platelet thrombin receptor antagonism with vorapaxar: a review on pharmacology and clinical trial development","author":"Franchi","year":"2015","journal-title":"Future Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0140","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0145","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with prior ischemic stroke","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.pcad.2015.08.009_bb0150","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2\u00b0P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.009_bb0155","doi-asserted-by":"crossref","first-page":"e001505","DOI":"10.1161\/JAHA.114.001505","article-title":"Efficacy and safety of vorapaxar as approved for clinical use in the United States","volume":"4","author":"Magnani","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2015.08.009_bb0160","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.114.013774","article-title":"Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial","volume":"131","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.08.009_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.08.009_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12265-013-9527-3","volume":"7","author":"Schulz","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.pcad.2015.08.009_bb0175","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11936-014-0300-y","article-title":"Platelet function testing in contemporary clinical and interventional practice","volume":"16","author":"Franchi","year":"2014","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0185","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","volume":"8","author":"Franchi","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.08.009_bb0190","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1753944713487781","article-title":"Update on platelet glycoprotein IIb\/IIIa inhibitors: recommendations for clinical practice","volume":"7","author":"Mu\u00f1iz-Lozano","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2015.08.009_bb0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2014.10.029","article-title":"Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials","volume":"65","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0210","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: a review on pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.pcad.2015.08.009_bb0215","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0220","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0225","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0230","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0235","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.009_bb0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11239-015-1233-3","article-title":"Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials","volume":"40","author":"Angiolillo","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pcad.2015.08.009_bb0255","article-title":"Switching P2Y12 receptor inhibitors in patients with coronary artery disease","author":"Rollini","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2015.08.009_bb0265","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jth.12472","article-title":"Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation","volume":"12","author":"Capra","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2015.08.009_bb0270","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/092986712803414240","article-title":"New perspectives in antiplatelet therapy","volume":"19","author":"Tello-Montoliu","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pcad.2015.08.009_bb0275","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.08.009_bb0280","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2015.08.009_bb0285","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.08.009_bb0290","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0295","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0300","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.08.009_bb0305","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0310","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jacc.2015.02.004","article-title":"The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: chasing a mirage","volume":"65","author":"Price","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.08.009_bb0315","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMe1413297","article-title":"Dual antiplatelet therapy after drug-eluting stents\u2014how long to treat?","volume":"371","author":"Colombo","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T10:16:55Z","timestamp":1582539415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062015000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0033062015000687"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2015.08.009","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2015.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}